Trial Profile
Safety of glycopyrrolate versus indacaterol in patients with chronic obstructive pulmonary disease: a 52-week study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Mar 2016
Price :
$35
*
At a glance
- Drugs Glycopyrrolate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Acronyms GEM3
- 08 Mar 2016 New trial record